Sales in the Dutasteride market are strong

Avodart's sales for the second year

Dutasteride drugs are expanding their influence in the domestic hair loss treatment market

Avodart and Propecia quarterly sales (units, data IQVIA)

The original drug, GSK Avodart, was the first in 2021 to go beyond Propecia (Finasteride), leading to the market for two consecutive years until last year.

 

In the case of generic, Dutasteride grows steeply and pursues the Finesteride quickly.

 

In the pharmaceutical industry, the new formulation product is cited as a variable in the market.

 

Boryeong's newly -made FINASTERIDE ingredient has been released, and Chong Kun Dang is developing a product of an injection formulation.

 

◆ Avodart's sales last year sales of 43.6 billion won VS Propecia's sales of 39.6 billion won According to IQVIA, a pharmaceutical market research firm on the 15th, GSK Avodart's sales last year were 43.6 billion won.

 

In 2021, the company increased by 4% from 41.9 billion won, changing the highest sales record.

 

If the scope is expanded to the last four years, sales growth will be even worse.

 

Avodart's sales, which amounted to 31.1 billion won in 2018, increased by 40% in four years.

 

In particular, in 2021, the company surpassed the existing market in Korea.

 

Propecia, the origin of hair loss treatment, has been steadily declining since 2019.

 

Propecia's sales amounted to 39.6 billion won last year.

 

In 2019, sales of 41.6 billion won were lowered to less than 40 billion won in 2021, and last year, it decreased even more.

 

In the pharmaceutical industry, price competitiveness is cited as Avodart's rapid growth.

 

AVODART is currently being supplied to 700 won per 1,700 won per 0.5mg product.

 

Avodart has lowered the price from 1300 won to 920 won as the patent expired in 2016.

 

In 2017, additional cuts to 700 won were lowered to half compared to Propecia.

 

◆ Dutasteride generic sales rising Dutasteride products also increased significantly.

 

Hyundai Pharm's Damodad's sales, which amounted to 5.9 billion won in 2021, increased 26% to 7.5 billion won last year.

 

Until 2019, annual sales amounted to only 900 million won, but more than eight times in three years.

 

Hanall Biopharma Pharma ADAMO also increased sales by 62% from 1.8 billion won to 3.1 billion won in a year.

 

In addition, sales increased by more than 10% in one year, including Huttex Pharmaceuticals Korea, Daewoong Bio DAEWOONG BIO DUTASTERIDE, DUTALID, and Dutaride Soft Cap.

 

In the case of Finasteride, the market size is still greater than Dutasteride, but the growth trend has slowed.

 

Momopecia increased 13% from 5.7 billion won in 2021 to 6.5 billion last year.

 

On the other hand, Genu One Science MYPECIA decreased by 16% from 5 billion won to 4.1 billion won during the same period, while JW SHINYAK MONAD decreased by 25% from 5.3 billion won to 4 billion won.

 

The sales of three of the six products, which recorded more than 3 billion won last year, fell compared to the previous year.